News: Selected Items from Google Alert - multiple sclerosis

Top-Line Results Positive for Alemtuzumab in MS
Medscape
July 12, 2011 — Results from the first CARE-MS trial are in, and they show a 55% reduction in relapse at 2 years in adults with relapsing-remitting multiple sclerosis treated with alemtuzumab (Campath, Genzyme) compared with those receiving interferon ...
See all stories on this topic »

Robert McBurney Named CEO of the Accelerated Cure Project for Multiple Sclerosis
Business Wire (press release)
(BUSINESS WIRE)--The Accelerated Cure Project for Multiple Sclerosis (ACP), a national nonprofit organization, today announced that it has named Robert McBurney, Ph.D., as its Chief Executive Officer. Dr. McBurney brings a wealth of expertise to this ...
See all stories on this topic »

Multiple Sclerosis Foundation Joins Sharecare as New Content Collaborator to ...
SYS-CON Media (press release)
ATLANTA, GA -- (Marketwire) -- 07/12/11 -- In line with their mission to provide the best health and wellness information online, Sharecare today announced the addition of the Multiple Sclerosis Foundation (MSF) to their robust network of expert ...
See all stories on this topic »

Canadian woman dies after undergoing controversial MS surgery
Montreal Gazette
By Matt McClure, Postmedia News July 11, 2011 CALGARY — A Calgary woman is the second Canadian to die after having an experimental vein treatment for multiple sclerosis. Within hours of having her neck veins opened at a California clinic on April 13, ...
See all stories on this topic »

Positive phase III MS results from Sanofi
PMLiVE
"In this two-year comparative study, the effect of alemtuzumab on reducing relapses versus Rebif, a leading drug for the treatment of multiple sclerosis, is impressive, and the safety profile is consistent with the phase II clinical trial experience," ...
See all stories on this topic »